1965-P: Glycemic Outcomes in CGM-Naïve vs. Experienced Patients Using Implantable CGM
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1965-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von RISHAB TANDON und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: The primary focus of this study is to compare the magnitude of HbA1c and GMI reduction in diabetic patients who are continuous glucose monitor (CGM)-naïve versus those transitioning from transcutaneous sensors. The study aims to determine the glycemic benefit of initiating an implantable CGM and whether transitioning to an implantable sensor provides superior clinical outcomes compared to traditional transcutaneous systems.
Methods
This single-center, 14-month study (Nov 2024-Dec 2025) analyzed n = 44 diabetic patients (mean age 67.16). Inclusion criteria required wear time > 75%, device duration > 3 months, and complete glycemic data. The cohort (mean wear time 93.8% ± 4.91%) included 38 patients on multiple daily injections and 27 on GLP-1 therapies. Paired t-tests assessed significance at 3 and 6 months.
Results
Baseline HbA1c for the entire cohort was 7.85% ± 1.94% (Naïve: 8.88% ± 2.83%; Prior transcutaneous: 7.51% ± 1.80%; Prior Eversense: 7.99% ± 0.91%; Prior dual-experienced with both transcutaneous and Eversense: 7.44% ± 1.59%). Total mean cohort Time in Range (TIR) was 78.11% ± 14.88%. Time spent 54-70 mg/dL was 1.23% ± 1.47%. Mean time below 54 mg/dL was 0.18% ± 0.28%. Post-initiation mean GMI at 2 weeks was 6.79% ± 0.49% (Naïve: 6.72% ± 0.25%; Prior transcutaneous: 6.78% ± 0.59%; Prior Eversense: 7.11% ± 0.44%; Dual: 6.62% ± 0.41%). At 3 months (n = 39), mean HbA1c reduction was 0.72% (p = 0.0068); naïve patients achieved 1.57% reduction and experienced patients achieved 0.53% (p = 0.0174). At 6 months (n = 27), mean reduction was 0.33% for the whole cohort.
Conclusion
Significant reductions in HbA1c and GMI indicate rapid stabilization upon initiating an implantable sensor. Naïve patients experienced a larger reduction. These outcomes exceed previously published results. Future analysis will calculate if implantable CGM usage results in fewer hospitalizations or ED visits compared to transcutaneous sensors or no CGM. Disclosure R. Tandon: None. J.B. Torres Serrano: None. B. Muldrow: None. S. Noorali: None. B.S. Baliga: Speaker's Bureau; Current; Abbott Diabetes. Speaker's Bureau; Ended; Novo Nordisk. Speaker's Bureau; Current; Boehringer Ingelheim International GmbH. Speaker's Bureau; Ended; AstraZeneca. Speaker's Bureau; Current; Beta Bionics, Inc. Stock/Shareholder; Current; Beta Bionics, Inc. Speaker's Bureau; Current; Xeris Pharmaceuticals, Inc., Eli Lilly and Company.
Zitieren
APA
TANDON, R., SERRANO, J. B. T., MULDROW, B., NOORALI, S., & BALIGA, B. S. (2026). 1965-P: Glycemic Outcomes in CGM-Naïve vs. Experienced Patients Using Implantable CGM. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1965-p
Vancouver
TANDON R, SERRANO JBT, MULDROW B, NOORALI S, BALIGA BS. 1965-P: Glycemic Outcomes in CGM-Naïve vs. Experienced Patients Using Implantable CGM. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1965-p
BibTeX
@article{TANDON2026,
author = {TANDON, RISHAB and SERRANO, JOAN B. TORRES and MULDROW, BRANDI and NOORALI, SEHRISH and BALIGA, BANTWAL S.},
title = {1965-P: Glycemic Outcomes in CGM-Naïve vs. Experienced Patients Using Implantable CGM},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1965-p}
}
EUVIMED